Key result
Rivaroxaban significantly reduced deep vein thrombosis compared to enoxaparin following total hip replacement (RR 0.21), whereas dabigatran showed comparable efficacy and safety to enoxaparin.
Why the study?
Does rivaroxaban or dabigatran reduce thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Population
Patients undergoing major orthopedic surgery, specifically total hip replacement and total knee replacement.
Comparison
New oral anticoagulants. vs Subcutaneous enoxaparin.
Design
Meta-analysis
Follow-up
35 to 90 days
Authors
Loading...
Rivaroxaban may be considered for superior DVT prevention after hip replacement despite bleeding risk; extends meta-analytic support for NOACs versus enoxaparin.
Systematic Review
Does rivaroxaban or dabigatran reduce thromboembolism compared to enoxaparin in patients undergoing total hip or knee replacement?
Relative Risk: 0.21 (95% CI 0.14–0.32)
Dabigatran and rivaroxaban show comparable overall efficacy and safety to enoxaparin for thromboprophylaxis after hip and knee replacement, though rivaroxaban significantly reduces DVT at the cost of increased major bleeding in hip replacement.
Hamidi et al. (2013) conducted a systematic review in Venous thromboembolism after total hip or knee replacement. Rivaroxaban and Dabigatran vs. Subcutaneous enoxaparin was evaluated on Deep vein thrombosis (DVT) following total hip replacement (Rivaroxaban vs Enoxaparin) (RR 0.21, 95% CI 0.14 to 0.32). Rivaroxaban significantly reduced deep vein thrombosis compared to enoxaparin following total hip replacement (RR 0.21), whereas dabigatran showed comparable efficacy and safety to enoxaparin.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: